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Obesity Reduces mTORC1 Activity in Mucosal-Associated
Invariant T Cells, Driving Defective Metabolic and Functional
Responses
Aisling O’Brien,*,1 Roisin M. Loftus,†,1 Marta M. Pisarska,‡,x,1 Laura M. Tobin,*,‡
Ronan Bergin,x Nicole A. W. Wood,†,x Cathriona Foley,† Arimin Mat,* Frances C. Tinley,x
Ciaran Bannan,† Gary Sommerville,{ Natacha Veerapen,‖ Gurdyal S. Besra,‖
Linda V. Sinclair,# Paul N. Moynagh,x,** Lydia Lynch,† David K. Finlay,†,††,‡‡
Donal O’Shea,*,‡,x,2 and Andrew E. Hogan*,‡,x,2
Obesity underpins the development of numerous chronic diseases, such as type II diabetes mellitus. It is well established that
obesity negatively alters immune cell frequencies and functions. Mucosal-associated invariant T (MAIT) cells are a population of
innate T cells, which we have previously reported are dysregulated in obesity, with altered circulating and adipose tissue
frequencies and a reduction in their IFN-g production, which is a critical effector function of MAIT cells in host defense. Hence,
there is increased urgency to characterize the key molecular mechanisms that drive MAIT cell effector functions and to identify
those which are impaired in the obesity setting. In this study, we found that MAIT cells significantly upregulate their rates of
glycolysis upon activation in an mTORC1-dependent manner, and this is essential for MAIT cell IFN-g production. Furthermore,
we show that mTORC1 activation is dependent on amino acid transport via SLC7A5. In obese patients, using RNA sequencing,
Seahorse analysis, and a series of in vitro experiments, we demonstrate that MAIT cells isolated from obese adults display
defective glycolytic metabolism, mTORC1 signaling, and SLC7A5 aa transport. Collectively, our data detail the intrinsic meta-
bolic pathways controlling MAIT cell cytokine production and highlight mTORC1 as an important metabolic regulator that is
impaired in obesity, leading to altered MAIT cell responses. The Journal of Immunology, 2019, 202: 3404–3411.
O
besity is a global epidemic, impacting over 600
million adults and 150 million children (1). Obesity
is linked to numerous chronic diseases, including
type II diabetes, cardiovascular disease, and certain cancers
(2). Underpinning the obesity-driven development of chronic
disease is systemic inflammation and immune cell dysregulation
(3, 4). We have previously reported the negative impact of obesity
on several immune cell populations, including invariant NK T cells,
NK cells, dendritic cells, and mucosal-associated invariant T (MAIT)
cells (5–8).
MAIT cells are a population of non-MHC–restricted T cells that
are important in the immune defense against bacterial and viral
infections. MAIT cells are early-responding T cells that are ca-
pable of rapidly producing multiple cytokines upon activation,
such as IFN-g, TNF-a, and IL-17 (9). MAIT cells are activated
when their invariant TCR recognize bacterial derivatives presented
on the MHC-like molecule MR1 (9, 10). MAIT cells can also be
activated in a TCR-independent manner via cytokine stimula-
tion (11). Dysregulated MAIT cell cytokine profiles have been
reported in several diseases, including obesity, arthritis, and viral
*Obesity Immunology Group, Education and Research Centre, St. Vincent’s Univer-
sity Hospital, University College Dublin, Dublin 4, Ireland; †School of Biochemistry
and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin 2,
Ireland; ‡National Children’s Research Centre, Dublin 12, Ireland; xDepartment of
Biology, Institute of Immunology, Maynooth University, Maynooth, County Kildare
W23 F2K8, Ireland; {Dana Farber Cancer Institute, Molecular Biology Core Facilities,
Boston, MA 02215; ‖School of Biosciences, University of Birmingham, Birmingham
B15 2TT, United Kingdom; #Division of Cell Signaling and Immunology, School
of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;
**School of Medicine, Dentistry and Biomedical Sciences, Wellcome–Wolfson Institute
for Experimental Medicine, Queen’s University, Belfast BT9 7BL, United Kingdom;
††School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute,
Trinity College Dublin, Dublin 4, Ireland; and ‡‡School of Pharmacy and Pharmaceu-
tical Sciences, Trinity College, Dublin 2, Ireland
1These authors contributed equally to the manuscript.
2Joint senior authorship.
ORCIDs: 0000-0001-9137-6625 (R.M.L.); 0000-0003-4685-7176 (R.B.); 0000-0001-
9046-2417 (C.F.); 0000-0001-9066-7957 (A.M.); 0000-0002-9288-8574 (C.B.);
0000-0003-4182-4236 (N.V.); 0000-0002-5605-0395 (G.S.B.); 0000-0003-1248-
7189 (L.V.S.); 0000-0003-2716-6679 (D.K.F.).
Received for publication December 7, 2018. Accepted for publication April 12, 2019.
This work was supported by the National Children’s Research Centre. A.E.H. and
D.O. are funded by the Health Research Board (HRB) (Grant RA-POR-2014-593),
and A.O. is funded by the HRB Centre for Health and Diet Research (Grant
HRC2014/13), both of which are funded by the Irish HRB. M.M.P., N.A.W.W.,
and A.E.H. are supported by the National Children’s Research Centre. The Seahorse
XF-96 Analyzer is funded by Science Foundation Ireland Grant 16/RI/3399.
A.O., R.M.L., M.M.P., L.M.T., N.A.W.W., F.C.T., R.B., and C.B. performed the
experiments and carried out analysis and approved the final manuscript as submitted.
A.M. recruited patients and controls. N.V. and G.S.B. provided MAIT cell reagents
and aided in the design of MAIT cell activation experiments. G.S. and C.F. performed
and analyzed the RNA sequencing. A.E.H., L.V.S., P.N.M., D.K.F., R.M.L., L.L., and
D.O. conceptualized and designed the study, analyzed the data, drafted the manu-
script, and approved the final manuscript as submitted.
The sequences presented in this article have been submitted to the Gene Expression
Omnibus under accession number GSE126169.
Address correspondence and reprint requests to Dr. Andrew E. Hogan, Institute
of Immunology, Maynooth University, Maynooth, County Kildare, Ireland. E-mail
address: Andrew.E.Hogan@mu.ie
The online version of this article contains supplemental material.
Abbreviations used in this article: BCH, 2-aminobicyclo- (2, 2, 1)-heptane-
2-carboxylic acid; 2DG, 2-deoxyglucose; ECAR, extracellular acidification rate;
FMO, flow minus-1; MAIT, mucosal-associated invariant T; OxPhos, oxidative phos-
phorylation; ps6, ribosomal S6 protein; RNA-Seq, RNA sequencing.
Copyright 2019 by TheAmerican Association of Immunologists, Inc. 0022-1767/19/$37.50
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1801600











infection (8, 12–15). The pathways controlling MAIT cell cyto-
kine responses are still under investigation.
It is now well established that cellular metabolism plays a
critical role in determining immune cell responses (16). Extrinsic
and intrinsic signals result in immune cell metabolic reprogramming,
which provides both the energy and biological intermediates required
for a robust immune response. Although different lymphocyte sub-
sets can adopt distinct metabolic signatures, in general, effector
lymphocytes are characterized by elevated glucose metabolism with
high rates of glycolysis and oxidative phosphorylation (OxPhos) (16).
Currently, there is a paucity of data regarding the metabolic
profile of MAIT cells or the importance of cellular metabolism in
driving MAIT cell effector functions. In this study, we show that
MAIT cells use glycolytic metabolism upon activation. Impor-
tantly, we show the requirement of this elevated rate of MAIT
cell glycolysis for cytokine production. Using RNA sequencing
(RNA-Seq) and Seahorse analysis, we show impaired glycolytic
metabolism in MAIT cells from obese individuals. We show that
MAIT cell glycolysis is dependent on mTORC1 activation, and in
obesity mTORC1 activation is reduced. Finally, we show that
mTORC1 activation in MAIT cells is dependent on amino acid
transport via SLC7A5. Collectively, our data show for the first time,
to our knowledge, the intrinsic metabolic pathways control-
ling MAIT cell cytokine production. Furthermore, we implicate a
novel amino acid–dependent regulatory mechanism that is con-
current with impaired MAIT cell functions in obesity.
Materials and Methods
Study cohorts
A cohort of 30 obese adults (mean body mass index 45.1) was enrolled into
this study, along with an age- and sex-matched cohort of healthy lean
controls (mean body mass index 24.7) (Supplemental Table I). Exclusion
criteria included patients with comorbid inflammatory conditions outside
of type II diabetes. Patients who smoke or are on anti-inflammatory
medications, GLP-1 therapies, or sodium-glucose cotransporter 2 inhibi-
tors were also excluded.
Preparation of PBMCs and flow cytometric analysis
PBMC samples were isolated by density centrifugation from fresh venous
blood samples. MAIT cell staining (1 3 106 PBMC) was performed using
specific surface mAbs (all Miltenyi Biotec), namely, CD3, CD161, CD8,
and TCRVa7.2 (Supplemental Fig. 3). Cell populations were acquired
using a BD FACSCanto II and analyzed using FlowJo software (Tree
Star). Results are expressed as a percentage of the parent population, as
indicated, and determined using flow minus-1 (FMO) and unstained
controls.
MAIT cell RNA-Seq and analysis
Highly pure MAIT cells were isolated from peripheral blood samples using
FACS (MoFlo XDP Sorter). RNAwas extracted from cells using the RNeasy
Mini Isolation Kit (Qiagen) and analyzed for quality control and quanti-
fication purposes using the Agilent Bioanalyzer and RNA Pico assay
(Agilent Technologies). RNA-Seq libraries were prepared using the
SMART-Seq v4 Ultra Low Input RNA Kit (Clontech Laboratories), and
next-generation sequencing was carried out using Illumina NextSeq 500
Single-End 75 bp (SE75) chemistry. Single-end RNA-Seq reads were
aligned to the human hg38 reference genome using Tophat2 (17)
and Bowtie (18) and the Ensembl gene annotation downloaded from the
BioMart Web site. The Qlucore Omics Explorer 3.2 software package
was used for visualization of RNA-Seq data. Qlucore Omics software
converted imported bam files into read counts and then normalized these
across the samples using the trimmed mean of M-values method (19).
Principal component analysis was performed using the default setting:
mean = 0, variance = 1 normalization based on 503 genes that passed
filtering by variance set at the level of 0.25. Gene set enrichment analysis
ranked genes based on the correlation between their expression, and the
normalized enrichment score reflected the degree to which Hallmark gene
sets from the Molecular Signatures Database were overrepresented from
the ranked gene list (20). Differential gene expression analysis was
implemented in the Qlucore, which performed a two-group comparison
between lean and obese MAIT cells. Genes downregulated in obesity
within the glycolysis and MTORC1 gene sets with a p value ,0.05
and log2 fold change .1.5 were represented in the heat maps generated
in Qlucore. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126169.
MAIT cell cytokine production analysis
MAIT cell cytokine production was determined by intracellular flow
cytometry. Briefly, PBMC (1 3 106) were cultured in the presence of a
protein transport inhibitor in media alone (control) or stimulated with
either TCR microbeads (Miltenyi Biotec), IL-12, IL-18, IL-12/18 (all
BioLegend), or a combination of TCR microbeads and IL-12/IL-18 for
18 h at 37˚C. Additionally, metabolic inhibitors were added as indicated:
rapamycin (20 nM), 2-deoxyglucose (2DG) (10 mM), oligomycin (2 mM),
or 2-aminobicyclo- (2, 2, 1)-heptane-2-carboxylic acid (BCH) (50 mM).
For acute glucose restriction experiments, PBMC were stimulated in media
containing less than 1 mM glucose for 18 h, after which cells were in-
vestigated for intracellular cytokine production by flow cytometry, as
previously described.
MAIT cell cytokine production by ELISpot
MAIT cell cytokine production was also determined by ELISpot. Briefly,
96-well ELISpot plate(s) were precoated with mAbs to IFN-g overnight
at 4˚C. Plates were washed in PBS to remove coating Ab and incubated at
37˚C for 1 h in complete RPMI. Previously isolated MAIT cells (2 3 105)
were cultured on the precoated plates either basally or stimulated with
IL-12/IL-18 and TCR microbeads at 37˚C for 18 h. ELISpot plates were
then washed with PBS/Tween for a minimum of six washes. Following
this, 50 ml of biotinylated mouse anti-human IFN-g was added and incu-
bated at room temperature for 3 h. ELISpot plates were washed in wash
buffer, and antibiotin-labeled Ab was added to the wells and incubated at
room temperature for 2 h. Finally, prefiltered BCIP/NBT solution (50 ml)
was added to each well and incubated at room temperature for 5 min or
until distinct dark spots appeared in the positive-control wells. Plates were
rinsed with tap water and allowed to air dry overnight. Cytokine expression
was analyzed using a semiautomated ELISpot plate reader.
MAIT cell glucose consumption analysis
Fresh PBMC (1 3 106 ml) were activated as previously described for 18 h;
cells were then washed and transferred to glucose-free media in the
presence of the fluorescent glucose analogue 2NBDG (Life Technologies)
for 2 h. Additionally, glut 1 expression was examined on basal and acti-
vated MAIT cells using an mAb specific for Glut-1 (R&D Systems). FMO
and unstimulated PBMC were used as negative controls.
MAIT cell Seahorse analysis
For real-time analysis of the extracellular acidification rate (ECAR) and
oxygen consumption rate of purified MAIT cells cultured under various
conditions, a Seahorse XF-96 Analyzer (Seahorse Bioscience) was used. In
brief, 200,000 purified, expanded MAIT cells were adhered to a CellTaq
(BD Pharmingen)–coated 96-well XF Cell Culture Microplate (Seahorse
Bioscience). Sequential measurements of ECAR and oxygen consumption
rate following addition of the inhibitors (Sigma-Aldrich) oligomycin
(2 mM), FCCP (0.5 mM), rotenone (100 nM) plus antimycin A (4 mM), and
2DG, (30 mM) allowed for the calculation of basal glycolysis, glycolytic
capacity, basal OxPhos, and maximal mitochondrial capacity. Each cell
culture condition was evaluated in quadruplicate, and 14 measurements
were made per sample.
MAIT cell mTOR analysis
PBMC (1 3 106 ml) were activated as previously described for 18 h.
mTOR activity in MAIT cells and CD8+ T cells was examined via the
phosphorylation of ribosomal S6 protein (pS6) (Cell Signaling Technol-
ogy) by flow cytometry. Rapamycin treatment was used as a control for
pS6 specificity and to determine the requirement of mTORC1 for IFN-g
production. FMO and unstimulated PBMC cells were used as negative
controls.
MAIT cell amino acid uptake and BCH experiments
PBMC or MAIT cells were used to investigate kynurenine uptake as de-
scribed in (21). Briefly, after surface Ab staining of samples, cells were
resuspended in 200 ml of warmed HBSS (13 106 cells) and incubated in a
water bath at 37˚C. Kynurenine (200 mM in HBSS), BCH (20 mM in
HBSS), and HBSS were warmed to 37˚C and added as appropriate. Uptake
was stopped after 4 min by PFA (final concentration 1%) for 30 min at
room temperature in the dark. After fixation, cells were washed twice in
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PBS/0.5% BSA and resuspend in PBS/0.5% BSA prior to acquisition on
flow cytometer. The 405-nm laser and 450/50 BP filter were used for
kynurenine fluorescence detection. For SLC7A5 inhibition experiments,
the concentration of amino acids in RPMI 1640 was diluted two-fold using
HBSS (Invitrogen) in the presence or absence of BCH (50 mM; Sigma-
Aldrich).
Statistics
Statistical analysis was completed using GraphPad Prism 6 Software. Data
are expressed as SEM. We determined differences between two groups
using Student t test and Mann–Whitney U test where appropriate. Analysis
across three or more groups was performed using ANOVA. Correlations
were determined using linear regression models and expressed using
Pearson or Spearman rank correlation coefficient, as appropriate. The
p values were expressed with significance set at ,0.05.
Study approval
Ethical approval was granted by theMedical Research Ethics Committees at
St. Vincent’s University Hospital. All patients gave written informed
consent prior to partaking in the study.
Results
Increased rates of glycolysis are essential for driving
MAIT cell IFN-g production
MAIT cells are potent producers of cytokine (IFN-g and TNF-a
among the most abundant). We show that in a stimulation-
dependent manner, a large proportion of MAIT cells produce
IFN-g and TNF-a but not IL-17, with the most robust response
seen after stimulation with anti-CD3/CD28–coated beads (TCR
beads) and the cytokines IL-12/IL-18 (Fig. 1A, Supplemental
Figs. 1A, 3). The metabolic pathways used by MAIT cells during
their cytokine production are currently undefined. We show that
MAIT cells express the major glucose transporter Glut-1 and
upregulate the uptake of the fluorescent 2DG analogue 2NBDG
upon activation in a stimulus-dependent manner (Fig. 1B–D).
These data suggested that MAIT cells upregulate glucose meta-
bolism. Therefore, we next performed detailed metabolic analysis
using the Seahorse extracellular flux analyzer. Interestingly, we
found MAIT cells specifically upregulate their rates of glycolysis
(Fig. 1E, 1F), but not OxPhos (Supplemental Fig. 2B), upon ac-
tivation. In addition, the glycolytic capacity, ECAR following
oligomycin injection, of MAIT cells also increased significantly
upon stimulation, which suggests that these cells are increasing
the expression of the glycolytic machinery (Fig. 1E). Therefore,
overall there was a pronounced shift toward glycolytic meta-
bolism in activated MAIT cells. To assess if cellular glycolysis
was required for cytokine production by MAIT cells, we used low
doses of the specific glycolytic inhibitor 2DG. The data showed
that MAIT cell IFN-g production was significantly reduced when
the rate of glycolysis was limited with 2DG (Fig. 1G, 1H). In-
terestingly, 2DG treatment had no impact on TNF-a production by
MAIT cells (Fig. 1I). In contrast, inhibition of mitochondrial
respiration with the ATP synthase inhibitor oligomycin did not
reduce IFN-g production by MAIT cells (Supplemental Fig. 2D,
2E) but did reduce TNF-a (Supplemental Fig. 2F). To further test
the requirement for glucose metabolism in driving MAIT cell
cytokine responses, we cultured MAIT cells under acute glucose
restriction and showed a strong inhibition of IFN-g, further
FIGURE 1. MAIT cells use glycolytic metabolism during IFN-g production. (A) Scatter plot showing MAIT cell production of IFN-g in a cohort of lean
adults (unstimulated versus stimulated with TCR microbead/IL-12/IL-18). (B) Scatter plot showing Glut-1 expression (MFI) on either basal or stimulated
MAIT cells from lean adults (n = 10). (C and D) Representative histograms and scatter plot showing 2NBDG uptake by MAIT cells stimulated with either
TCR microbeads, IL-12, IL-18, both IL-12 and IL-18, or TCR microbeads and IL-12/IL-18 (n = 3). (E and F) Scatter plot and representative Seahorse traces
displaying MAIT cells ECAR rates in either basal (open circles) or stimulated (gray circles) MAIT cells from lean adults. Data representative of six
independent experiments. (G) Representative flow cytometry dot plots and scatter plot displaying the effect of 2DG treatment on IFN-g production by
stimulated MAIT cells (n = 10). (H) Representative ELISpot wells and scatter plot displaying the effect of 2DG treatment (bottom panel) on IFN-g production
by stimulated MAIT cells (n = 5). (I) Scatter plot displaying the effect of 2DG treatment on TNF-a production by stimulated MAIT cells (n = 10). (J) Scatter
plot showing impact of acute glucose restriction (AGR) on IFN-g production by stimulated MAIT cells from lean adults (n = 5). Data representative of five
independent experiments. Statistical comparisons using Student t test or ANOVA. Data representative of a minimum of 10 independent experiments unless
otherwise stated. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001. MFI, mean fluorescence intensity.
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supporting our findings that MAIT cell IFN-g production is de-
pendent on glycolytic metabolism (Fig. 1J).
Defective IFN-g production by MAIT cells in obesity parallels
defective cellular metabolism
We have previously reported defective MAIT cells in obese in-
dividuals, including impaired IFN-g production, which we confirm
in an expanded cohort of obese adults (Fig. 2A). Interestingly, in
our obese cohort, we did not observe defective CD8+ T cell IFN-g
production (Fig. 2B). To investigate the mechanism(s) driving de-
fective IFN-g production by MAIT cells in obesity, we performed
RNA-Seq of MAIT cells isolated from five lean and four obese
individuals. Normal enrichment score analysis highlighted a re-
duction in the glycolytic metabolism pathway (Fig. 2C). To inves-
tigate the significance of the reduced glycolytic metabolism in
obesity, Glut-1 expression and 2NBDG uptake assays were
performed. The data showed that MAIT cells from obese adults
show no significant difference in Glut-1 expression (Fig. 2D).
However, there was a significant decrease in the uptake of 2NBDG
in stimulated MAIT cells from obese individuals when compared
with healthy adults (Fig. 2E). Detailed metabolic analysis was
used to confirm the alterations in MAIT cell glycolytic meta-
bolism between healthy and obese MAIT cells. In line with the
reduced glycolytic gene expression and glucose uptake, activated
MAIT cells from obese adults do not increase their rate of gly-
colysis (Fig. 2F, 2G). Indeed, MAIT cells from obese adults show
reduced glycolytic capacity when compared with lean adults
(Fig. 2H). Furthermore, acute glucose restriction had no additional
impact/reduction on IFN-g production in MAIT cells from obese
individuals in comparison with the significant effect observed in
MAIT cells from lean individuals (Fig. 2I). These data confirm
that MAIT cells from obese adults are not performing increased
rates of glycolysis during their activation.
mTORC1 activity is essential for driving MAIT cell glycolysis
and is reduced in obesity
The signaling complex mTORC1 acts as both a nutrient sensor and
a central metabolic regulator of effector immune cells. Studies
have shown that mTORC1 is intrinsically linked with glycolytic
metabolism in effector lymphocytes (22, 23). Strikingly, our
RNA-Seq data revealed defective mTORC1 signaling. (Fig. 3A).
To investigate a role for mTORC1 in driving MAIT cell meta-
bolism, we measured mTORC1 activity in MAIT cells upon
stimulation and demonstrate a robust increase as measured via the
phosphorylation of pS6 (Fig. 3B, 3C). Importantly, these elevated
levels of pS6 were prevented by the mTORC1 inhibitor rapamycin,
demonstrating the specificity of this assay for mTORC1 signaling
(Fig. 3D). We next investigated if mTORC1 signaling is required
for increased rates of glycolysis in activated MAIT cells. Indeed,
MAIT cells stimulated in the presence of rapamycin had significantly
lower levels of glycolysis (Fig. 3E, 3F). As expected, rapamycin
treatment had no significant impact on the ECAR of MAIT cells
FIGURE 2. MAIT cells from obese adults display defective glycolytic metabolism. (A) Scatter plot displaying MAIT cell production of IFN-g in a
cohort of lean (white circles) and obese (gray circles) adult (unstimulated versus stimulated with TCR microbead/IL-12/IL-18) (n = 15). (B) Scatter plot
displaying CD8 T cell production of IFN-g in a cohort of lean (white circles) and obese (gray circles) adult (unstimulated versus stimulated with TCR
microbead/IL-12/IL-18) (n = 15). (C) Heat map depicting differentially downregulated genes (p value , 0.05) within the glycolysis gene set in MAIT cells
isolated from lean and obese donors (n = 5 and 4, respectively). (D) Scatter plot showing Glut-1 MFI on either basal or stimulated MAIT cells from lean
(white circles) or obese (gray circles) donors (n = 10). (E) Scatter plot showing 2NBDG MFI on either basal or stimulated MAIT cells from lean (white
circles) or obese (gray circles) donors. (F) Representative Seahorse trace displaying MAIT cell ECAR rates in either basal (open circles) or stimulated (gray
circles) MAIT cells from an obese adult with representative stimulated lean donor (black circles). (G and H) Scatter plot displaying glycolysis levels
(ECAR) or glycolytic capacity (ECAR post–oligomycin treatment) from lean (white circles) or obese (gray circles) donors (n = 6). (I) Scatter plot showing
impact of acute glucose restriction (AGR) on IFN-g production by stimulated MAIT cells from lean (white circles) or obese (gray circles) adults. Data
representative of a minimum of five independent experiments unless otherwise stated. Statistical comparisons using Student t test or ANOVA. Error bars
represent SEM. *p , 0.05, **p # 0.01. MFI, mean fluorescence intensity.
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from obese donors (Fig. 3G). We show that rapamycin treatment
of activated MAIT cells from lean individuals inhibits IFN-g, and
this regulation occurs at an mRNA level (Fig. 3H, 3I). Together,
these data demonstrate that mTORC1 is required for metabolic
and functional MAIT cell responses. Indeed, the data show that
activation-induced mTORC1 activity was significantly reduced in
MAIT cells from obese adults (Fig. 3J). Similar to CD8+ T cell
IFN-g production, we observed no difference in CD8+ T cell
mTORC1 activity between lean and obese donors (Fig. 3K). Collec-
tively, these data highlight an important role for mTORC1 signaling in
MAIT cell metabolism and highlight obesity-associated defects in
mTORC1 as a possible driver of defective MAIT cell function.
mTORC1 activity is dependent on amino acid flux via SLC7A5,
which is diminished in obesity
The data thus far highlight a crucial role for mTORC1 signaling in
controlling MAIT cell metabolism and function. We next inves-
tigated the upstream regulators of mTOR activity in MAIT cells in
the hopes that it may shed light on the cause behind the defective
mTORC1 signaling observed in obeseMAIT cells. Previous studies
have highlighted the importance of amino acid transport through
the system L amino acid transporter, SLC7A5, in controlling
mTOR activity in primary T cells (24). To assess whether amino
acid transport controls mTORC1 activity in MAIT cells, we first
investigated amino acid transport in MAIT cells using a recently
described flow cytometric–based assay (21). We show that MAIT
cells readily uptake exogenous amino acids (as determined by
active transport of the fluorescent system L transporter substrate
kynurenine) (Fig. 4A, 4B). Furthermore, we show that treatment
with the system L amino acid transport inhibitor BCH reduced
kynurenine uptake by MAIT cells (Fig. 4C, 4D). We next in-
vestigated if MAIT cells from obese donors had altered amino
acid uptake. Interestingly, we observed a significant decrease in
uptake through system L transport compared with MAIT cells
from lean donors (Fig. 4E, 4F). To investigate this reduction,
we measured the expression of the predominant system L
amino acid transporter expressed in T cells, SLC7A5, and show
reduced mRNA expression in obese donors (Fig. 4G). Finally,
using BCH treatment, we investigated the impact of this di-
minished amino acid uptake on mTORC1 activity and gly-
colytic metabolism in MAIT cells from healthy donors. We
observed reduced mTORC1 activation and strong abrogation of
glycolytic metabolism with BCH (Fig. 4H–K). As expected, we
observed reduced IFN-g production by MAIT cells treated with
BCH (Fig. 4L). These data implicate for the first time, to our
knowledge, a crucial role for amino acid availability in regu-
lating MAIT cell metabolism and function in obesity.
Discussion
In this study, we show definitively that MAIT cells increase their
rates of glucose uptake and glycolysis upon activation. We also
show that this increased rate ofMAIT cell glycolysis is essential for
driving IFN-g production. Furthermore, we identify mTORC1
as a key metabolic regulator that controls the rate of MAIT cell
FIGURE 3. MAIT cell glycolytic metabolism is dependent on mTORC1 activation, which displays defects in obesity. (A) Heat map depicting differ-
entially downregulated genes (p value , 0.05) within the mTORC1 gene set in MAIT cells isolated from lean and obese donors (n = 5 and 4, respectively).
(B and C) Representative histogram and scatter plot showing the activation of mTORC1 (phosphorylation of S6) in MAIT cells stimulated with either TCR
microbeads, IL-12, IL-18, both IL-12 and IL-18, or TCR microbeads, IL-12 and IL-18 (n = 3). (D) Representative histogram showing the inhibition of S6
phosphorylation by rapamycin in stimulated MAIT cells. (E) Representative Seahorse traces displaying MAIT cell ECAR rates in either basal (open
circles), stimulated (gray circles), or rapamycin-treated (open squares) in MAIT cells from lean donors. (F) Scatter plot displaying ECAR levels in
stimulated (gray circles) or rapamycin-treated (white circles) MAIT cells from lean donors. (G) Scatter plot detailing effect of rapamycin on ECAR rates in
stimulated obese MAIT cells. (H) Scatter plot detailing effect of rapamycin on IFN-g production by stimulated MAIT cells from lean donors. (I) Scatter plot
detailing effect of rapamycin on IFN-g mRNA in MAIT cells from lean donors. (J) Scatter plot showing pS6 MFI in either basal or stimulated MAIT cells
from lean (white circles) or obese (gray circles) donors. (K) Scatter plot showing pS6 MFI in either basal or stimulated CD8 T cells from lean (white circles)
or obese (gray circles) donors. Data representative of a minimum of five independent experiments unless otherwise stated. Statistical comparisons using
Student t test or ANOVA. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001.
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metabolism and thereby effector molecule production. We show
that mTORC1 activation is under the control of amino acid uptake
by the cell and expression of the system L amino acid transporter,
SLC7A5. We previously reported that MAIT cells isolated from
obese individuals are functionally defective. To understand the
mechanisms at play, we used RNA-Seq to identify alterations in
the gene expression of MAIT cells isolated from obese individu-
als. These analyses highlighted alterations in both glycolytic and
mTORC1 pathways in MAIT cells isolated from obese individu-
als. Indeed, we confirm our sequencing data by showing reduced
rates of glycolysis and mTORC1 activity in MAIT cells from
obese adults, which parallel the loss of IFN-g production reported
in obesity (8). Finally, we provide evidence that defects in amino
acid transport contribute to the described defective MAIT cell
metabolism in obese patients.
MAIT cells are potent effector T cells, capable of rapidly
producing multiple cytokines (9). During viral infections, activa-
tion of the MAIT cell is independent of the TCR but dependent
on IL-18. Data from Slichter and colleagues (11) show that
MAIT cells respond weakly to TCR stimulation in the absence of
secondary stimulation by cytokine. Our data support this finding,
showing that MAIT cells respond most strongly when stimulated
via the TCR and cytokine receptors, specifically IL-18 and IL-12.
The pathways regulating MAIT cell cytokine production are
poorly understood; however, a recent study by Zinser and col-
leagues (25) provided evidence that MAIT cell production of
granzyme B was dependent on glycolytic metabolism. In other
effector lymphocytes, it is well established that the cytokine
profiles are regulated by intrinsic cellular metabolism (26–28).
Activated T cells have been shown to have a large glucose
requirement, especially Th 1 and 17 subsets along with CD8+
cells (27). We show that MAIT cells express the glucose
transporter Glut-1 and upon cytokine stimulation increase their
uptake of the fluorescent 2DG analogue 2NBDG. Like the
cytokine responses, MAIT cells increased 2NBDG uptake with
TCR stimulation; however, the greatest increases in glucose
uptake were observed with TCR–cytokine costimulation. This
is in keeping with the requirement for greater amounts of
energy and biological intermediates following TCR/cytokine
stimulation.
Studies in effector populations such as CD8+ T cells and NK
cells have demonstrated that the cytokine production by these cells
is dependent on glycolytic metabolism (20, 27). We investigated
the metabolic pathways used by MAIT cells using the Seahorse
extracellular flux analyzer and show that MAIT cells are glyco-
lytic cells, increasing their rates of glycolysis upon activation.
Interestingly, in contrast to NK cells, MAIT cells do not display
parallel increases in OxPhos (28). To link MAIT cell glycolytic
metabolism to cytokine production, we used the glycolytic path-
way inhibitor 2DG and show that at low doses it strongly inhibits
MAIT cell production of IFN-g. We also show that acute restriction
of glucose during MAIT cell activation significantly impacted their
activation, confirming their glycolytic requirements. Interestingly,
2DG treatment did not impact TNF-a production by MAIT cells,
whereas treatment with oligomycin reduced TNF-a production but
not IFN-g. Previous studies in macrophages have described the
differential regulation of TNF-a, showing that 2DG blocks IL-1b
but not TNF-a. This suggests differential metabolic regulation of
TNF-a production in MAIT cells.
We and others have previously reported that MAIT cells are
defective in obese adults, although the mechanism(s) underpin-
ning their dysregulation are unknown (8, 29). To elucidate the
mechanisms driving the alterations in cytokine production, we
performed RNA-Seq of MAIT cells isolated from lean and obese
adults. We observed alterations in the expression over 400 genes
between lean and obese donors, and principal component analysis
FIGURE 4. mTORC1 activation in MAIT cells is dependent on amino acid uptake via SLC7A5, which is defective in obesity. (A and B) Representative
histogram and scatter plot showing Kynurenine (Kyn) uptake by MAIT cells compared with HBSS control (no Kyn) (n = 10). (C and D) Representative
histogram and scatter plot showing the effect of BCH (50 mM) on Kyn uptake by MAIT cells (n = 10). (E and F) Representative histogram and scatter plot
showing Kyn uptake by MAIT cells from a lean (open histogram) or obese donor (gray histogram) (n = 10). (G) Scatter plot showing SLC7A5 mRNA
expression in MAIT cells from lean or obese donors (n = 5). (H and I) Representative histogram and scatter plot showing the effect of BCH (50 mM) on the
activation of mTORC1 (pS6) in TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). (J and K) Representative Seahorse trace and scatter plot showing the
effect of BCH (50 mM) on the ECAR of TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). (L) Scatter plot showing the effect of BCH (50 mM) on IFN-g
production by TCR-/IL-12–/IL-18–activated MAIT cells (n = 4). Data representative of a minimum of five independent experiments unless otherwise stated.
Statistical comparisons using Student t test or ANOVA. Error bars represent SEM. *p , 0.05, **p # 0.01, ***p , 0.001.
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separated MAIT cells isolated from lean donors from MAIT cells
isolated from obese donors. Pathway analysis revealed changes in
several cellular metabolism pathways, including the downregula-
tion of genes associated with glycolytic metabolism in MAIT cells
isolated from obese individuals. To confirm our sequencing data, we
performed a series of experiments, which show for the first time,
to our knowledge, that glycolytic metabolism is defective in
MAIT cells isolated from obese adults. This parallels our recent
study showing defective glycolytic metabolism in NK cells from
obese adults (30). In contrast to NK cells and the MAIT data from
obese adults presented in this study, we previously reported that in a
cohort of obese children there was altered NK cell metabolism with
elevated rates of glycolysis, which may suggest that chronic
activation of glycolytic machinery in childhood obesity results in
a failure later in life (31).
The mTOR complex is highlighted both as an important
signaling complex and regulator of metabolism in immune
populations such as CD8+ T cells and NK cells (20, 26, 32). Our
data identify mTORC1 as a key regulator of MAIT cell meta-
bolism. In this study, we show that MAIT cells increase mTORC1
activity upon activation, which is essential for the elevated levels
of MAIT cell metabolism upon activation. Finally, our sequencing
data highlighted reductions in mTORC1 signaling in MAIT cells
isolated from obese individuals. We show diminished mTORC1
activation in MAIT cells but not classical CD8+ T cells isolated
from obese individuals as compared with lean controls. Previous
studies show that inhibition of mTORC1 with rapamycin results
in reduced effector immune cell functions (20, 33). Indeed, inhi-
bition of mTORC1 activation with rapamycin inhibited IFN-g
production, which is in line with reduced rate of glycolysis ob-
served in rapamycin-treated MAIT cells and the requirement of
glycolysis for MAIT cell IFN-g production. These findings con-
tribute to our understanding as to why MAIT cell functional re-
sponses are impaired in obesity.
To investigate why mTOR activity is diminished in MAIT cells
from obese donors, we investigated the upstream regulators of
mTOR. Previous studies by our collaborators have extensively
shown that AKT is dispensable for T cell metabolism and NK cell
metabolism but highlight amino acid transport as an important
regulator of mTORC1 activity (24, 26, 34, 35). To this end,
we show that MAIT cell activation of mTORC1 and subsequent
upregulation of glycolytic metabolism and IFN-g production is
dependent on amino acid transport into the cell. We also show
that MAIT cells from obese donors have reduced expression
of the system L amino acid transporter SLC7A5 and thus re-
duced amino acid uptake. Numerous studies have highlighted the
dysregulation of obesity on amino acid metabolism, in particular
branched chained amino acids such as leucine, which is the
candidate amino acid implicated in the activation of mTOR in
T cells (36–41).
Collectively, our data show that MAIT cells use glycolytic
metabolism during their production of IFN-g and that this process
is regulated by mTORC1, which in turn is dependent on amino
acid flux into the cell. In obesity, RNA-Seq of MAIT cells
revealed downregulation of genes involved in both glycolytic
metabolism and mTORC1 signaling. We confirmed these alter-
ations using a series of in vitro experiments. These findings pro-
vide a mechanism for the reported alterations in MAIT cell IFN-g
production in obesity and may help us to understand the alter-
ations of MAIT cells in other human diseases such as hepatitis
C virus, malignant myeloma, and colorectal cancer (42–44).
Finally, understanding the metabolic pathways controlling MAIT
cell activation may highlight novel targets for controlling their
functions in disease (45).
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44. Sundström, P., F. Ahlmanner, P. Akéus, M. Sundquist, S. Alsén, U. Yrlid,
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